Form 4: Enliven Therapeutics CFO Benjamin Hohl Exercises Options and Sells Shares
SEC Form 4 Filing
Enliven Therapeutics CFO Benjamin Hohl exercised stock options and sold shares on June 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On June 27, 2024, Benjamin Hohl, the CFO of Enliven Therapeutics, exercised options to purchase 4,250 shares of common stock at a price of $2.48 per share.
- Simultaneously, Hohl sold 1,280 shares at a weighted average price of $21.7946, 1,830 shares at a weighted average price of $22.5756, and 1,140 shares at a weighted average price of $23.4308.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
- Following these transactions, Hohl directly owns 0 shares of common stock and 212,620 derivative securities (stock options).
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports transactions by an officer under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects.
Comparison to Industry Standards
- Insider transactions are common, and the use of Rule 10b5-1 trading plans is a standard practice to avoid accusations of trading on non-public information.
- Comparable companies in the biotech sector, such as Amgen or Gilead, also have executives who regularly trade shares, with these transactions being publicly disclosed through Form 4 filings.
- The size and frequency of these transactions are generally in line with industry norms for executives at similarly sized companies.
Stakeholder Impact
- The transactions may have a minor impact on shareholders as they reflect insider trading activity, but the existence of a 10b5-1 plan mitigates concerns about opportunistic trading.
Key Dates
| Date | Description |
|---|---|
| 06/26/2023 | Date of adoption of Rule 10b5-1 trading plan |
| 08/02/2022 | Initial vesting date for stock options (one-fourth of shares) |
| 06/27/2024 | Date of option exercise and share sales |
| 08/02/2031 | Expiration date of stock options |
| 07/01/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.